1. Home
  2. PCAP vs IMRX Comparison

PCAP vs IMRX Comparison

Compare PCAP & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PCAP

ProCap Acquisition Corp Class A Ordinary Shares

HOLD

Current Price

$10.23

Market Cap

324.1M

Sector

N/A

ML Signal

HOLD

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$5.20

Market Cap

340.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCAP
IMRX
Founded
2025
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
324.1M
340.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PCAP
IMRX
Price
$10.23
$5.20
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$17.20
AVG Volume (30 Days)
39.2K
771.7K
Earning Date
01-01-0001
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.75
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.01
$1.40
52 Week High
$11.42
$10.08

Technical Indicators

Market Signals
Indicator
PCAP
IMRX
Relative Strength Index (RSI) 57.20 44.61
Support Level $10.16 $4.83
Resistance Level $10.25 $5.36
Average True Range (ATR) 0.01 0.33
MACD -0.00 -0.06
Stochastic Oscillator 50.00 13.79

Price Performance

Historical Comparison
PCAP
IMRX

About PCAP ProCap Acquisition Corp Class A Ordinary Shares

ProCap Acquisition Corp is a blank check company.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: